logo
Plus   Neg
Share
Email

Novartis Reaches Licensing, Supply Agreement With Spark For LUXTURNA Outside US

Novartis (NVS) announced a licensing agreement with Spark Therapeutics covering development, registration and commercialization rights to voretigene neparvovec in markets outside the US. Novartis will make an upfront payment as well as pay milestones and royalties to Spark Therapeutics. The market authorization application with the European Medicines Agency was filed on July 31, 2017. Commercialization rights will be transferred to Novartis upon successful completion of registration and issuance of market authorization.

Voretigene neparvovec, known as LUXTURNA in the US, received FDA approval on December 19, 2017 as a one-time gene therapy to restore functional vision in children and adult patients with biallelic mutations of the RPE65 (retinal pigment epithelial 65 kDa protein) gene. Spark Therapeutics retains exclusive rights for LUXTURNA in the US.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc.'s (AMZN) Chief Executive Jeff Bezos has told the company's employees said that the tech giant is not too big to fail, according to media reports. Shares of Nordstrom Inc. (JWN) slipped 10 percent in extended hours on Thursday after the department store chain's full-year revenue outlook fell short of Street estimates. Seattle-based Nordstrom's third-quarter profit dropped to $67 million or $0.39 per share from $114 million or $0.67 per share... Shares of Nvidia Corp. (NVDA) plunged 16% in extended session on Thursday after chip designer's third-quarter revenues and fourth quarter outlook fell short of Wall Street estimates. Santa Clara, California-based Nvidia's third-quarter profit surged to $1.23 billion or $1.97 per share from $838 million...
Follow RTT